Nose-to-brain delivery of antipsychotics using nanotechnology: a review

References

• Siskind D, Kisely S. Balancing body and mind: selecting the optimal antipsychotic. Lancet. 2019;394(10202):900–902.
   PubMed Web of Science ®Google Scholar
• Siskind D, McCartney L, Goldschlager R, et al. Clozapine v. first- and second-generation antipsychotics in treatment-refractory schizophrenia: systematic review and meta-analysis. Br J Psychiatry. 2016;209(5):385–392.
   PubMed Web of Science ®Google Scholar
• Haddad PM, Sharma SG. Adverse effects of atypical antipsychotics: differential risk and clinical implications. CNS Drugs. 2007;21(11):911–936.
   PubMed Web of Science ®Google Scholar
• Marteene W, Winckel K, Hollingworth S, et al. Strategies to counter antipsychotic-associated weight gain in patients with schizophrenia. Expert Opin Drug Saf. 2019;18(12):1149–1160.
   PubMed Web of Science ®Google Scholar
• Chen S-Y, Ravindran G, Zhang Q, et al. Treatment strategies for clozapine-induced sialorrhea: a systematic review and meta-analysis. CNS Drugs. 2019;33(3):225–238.
   PubMed Web of Science ®Google Scholar
• Siskind D, Sidhu A, Cross J, et al. Systematic review and meta-analysis of rates of clozapine-associated myocarditis and cardiomyopathy. Aust N Z J Psychiatry. 2020:0004867419898760.
   Web of Science ®Google Scholar
• Mittal D, Ali A, Md S, et al. Insights into direct nose to brain delivery: current status and future perspective. Drug Deliv. 2014;21(2):75–86.
   PubMed Web of Science ®Google Scholar
• Djupesland PG, Messina JC, Mahmoud RA. The nasal approach to delivering treatment for brain diseases: an anatomic, physiologic, and delivery technology overview. Ther Deliv. 2014;5(6):709–733.
   PubMedGoogle Scholar
• Dahl AR, Hadley WM. Nasal cavity enzymes involved in xenobiotic metabolism: effects on the toxicity of inhalants. Crit Rev Toxicol. 1991;21(5):345–372.
   PubMed Web of Science ®Google Scholar
• Abou-Setta AM, Mousavi SS, Spooner C, et al. First-generation versus second-generation antipsychotics in adults: comparative effectiveness. Rockville (MD): Agency for Healthcare Research and Quality (US); 2012 Aug. ( Comparative Effectiveness Reviews, No. 63).
   Google Scholar
• Halfdanarson O, Zoega H, Aagaard L, et al. International trends in antipsychotic use: a study in 16 countries, 2005–2014. Eur Neuropsychopharmacol. 2017;27(10):1064–1076.
   PubMed Web of Science ®Google Scholar
• Stroup TS, Gray N. Management of common adverse effects of antipsychotic medications. World Psychiatry. 2018;17(3):341–356.
   PubMed Web of Science ®Google Scholar
• Wishart DS, Feunang YD, Guo AC, et al. DrugBank 5.0: a major update to the DrugBank database for 2018. Nucleic Acids Res. 2018;46(D1):D1074–d82.
   PubMed Web of Science ®Google Scholar
• Laszcz M, Witkowska A. Studies of phase transitions in the aripiprazole solid dosage form. J Pharmaceut Biomed. 2016;117:298–303.
   PubMed Web of Science ®Google Scholar
• Zeng F, Wang L, Zhang W, et al. Formulation and in vivo evaluation of orally disintegrating tablets of clozapine/hydroxypropyl-β-cyclodextrin inclusion complexes. AAPS PharmSciTech. 2013;14(2):854–860.
   PubMed Web of Science ®Google Scholar
• Jawahar N, Hingarh PK, Arun R, et al. Enhanced oral bioavailability of an antipsychotic drug through nanostructured lipid carriers. Int J Biol Macromol. 2018;110:269–275.
   PubMed Web of Science ®Google Scholar
• DeVane CL, Nemeroff CB. Clinical pharmacokinetics of quetiapine. Clin Pharmacokinet. 2001;40(7):509–522.
   PubMed Web of Science ®Google Scholar
• Saibi Y, Sato H, Tachiki H. Developing in vitro-in vivo correlation of risperidone immediate release tablet. AAPS PharmSciTech. 2012;13(3):890–895.
   PubMed Web of Science ®Google Scholar
• Bourganis V, Kammona O, Alexopoulos A, et al. Recent advances in carrier mediated nose-to-brain delivery of pharmaceutics. Eur J Pharm Biopharm. 2018;128:337–362.
   PubMed Web of Science ®Google Scholar
• Beule AG. Physiology and pathophysiology of respiratory mucosa of the nose and the paranasal sinuses. GMS Curr Top Otorhinolaryngol Head Neck Surg. 2010;9:Doc07.
   PubMedGoogle Scholar
• Lochhead JJ, Wolak DJ, Pizzo ME, et al. Rapid transport within cerebral perivascular spaces underlies widespread tracer distribution in the brain after intranasal administration. J Cereb Blood Flow Metab. 2015;35(3):371–381.
   PubMed Web of Science ®Google Scholar
• Arora P, Sharma S, Garg S. Permeability issues in nasal drug delivery. Drug Discovery. 2002;7(18):967–975.
   Google Scholar
• Welge-Lüssen A. Re-establishment of olfactory and taste functions. GMS Curr Top Otorhinolaryngol Head Neck Surg. 2005;4:Doc06.
   PubMedGoogle Scholar
• Gänger S, Schindowski K. Tailoring formulations for intranasal nose-to-brain delivery: A review on architecture, physico-chemical characteristics and mucociliary clearance of the nasal olfactory mucosa. Pharmaceutics. 2018;10(3):116.
   PubMed Web of Science ®Google Scholar
• Sultan‐Styne K, Toledo R, Walker C, et al. Long‐term survival of olfactory sensory neurons after target depletion. J Comp Neurol. 2009;515(6):696–710.
   PubMed Web of Science ®Google Scholar
• Dhuria SV, Hanson LR, Frey WH. Intranasal delivery to the central nervous system: mechanisms and experimental considerations. J Pharm Sci. 2010;99(4):1654–1673.
   PubMed Web of Science ®Google Scholar
• Gizurarson S. Anatomical and histological factors affecting intranasal drug and vaccine delivery. Curr Drug Deliv. 2012;9(6):566–582.
   PubMed Web of Science ®Google Scholar
• Grassin-Delyle S, Buenestado A, Naline E, et al. Intranasal drug delivery: an efficient and non-invasive route for systemic administration: focus on opioids. Pharmacol Ther. 2012;134(3):366–379.
   PubMed Web of Science ®Google Scholar
• Bitter C, Suter-Zimmermann K, Surber C. Nasal drug delivery in humans. Curr Probl Dermatol. 2011;40:20–35.
   PubMedGoogle Scholar
• Hong SS, Oh KT, Choi HG, et al. Liposomal formulations for nose-to-brain delivery: recent advances and future perspectives. Pharmaceutics. 2019;11:10.
   Web of Science ®Google Scholar
• Laffleur F. Mucoadhesive therapeutic compositions: a patent review (2011–2014). Expert Opin Ther Pat. 2016;26(3):377–388.
   PubMed Web of Science ®Google Scholar
• Morrison EE, Costanzo RM. Morphology of olfactory epithelium in humans and other vertebrates. Microsc Res Techniq. 1992;23(1):49–61.
   PubMed Web of Science ®Google Scholar
• Costa C, Moreira JN, Amaral MH, et al. Nose-to-brain delivery of lipid-based nanosystems for epileptic seizures and anxiety crisis. J Control Release. 2019;295:187–200.
   PubMed Web of Science ®Google Scholar
• Pires A, Fortuna A, Alves G, et al. Intranasal drug delivery: how, why and what for? J Pharm Pharm Sci. 2009;12(3):288–311.
   PubMed Web of Science ®Google Scholar
• Musumeci T, Bonaccorso A, Puglisi G. Epilepsy disease and nose-to-brain delivery of polymeric nanoparticles: an overview. Pharmaceutics. 2019;11:3.
   Web of Science ®Google Scholar
• Chen J, Wang J, Wei L, et al. Therapeutic intranasal delivery for stroke and neurological disorders. Switzerland: Springer; 2019.
   Google Scholar
• Kaliner M, Shelhamer JH, Borson B, et al. Human respiratory mucus. Am Rev Respir Dis. 1986;134(3):612–621.
   PubMed Web of Science ®Google Scholar
• Ozsoy Y, Güngör S. Nasal route: an alternative approach for antiemetic drug delivery. Expert Opin Drug Deliv. 2011;8(11):1439–1453.
   PubMed Web of Science ®Google Scholar
• Cone RA. Barrier properties of mucus. Adv Drug Deliv Rev. 2009;61(2):75–85.
   PubMed Web of Science ®Google Scholar
• Merkus FW, Verhoef JC, Schipper NG, et al. Nasal mucociliary clearance as a factor in nasal drug delivery. Adv Drug Deliv Rev. 1998;29(1–2):13–38.
   PubMed Web of Science ®Google Scholar
• Graff CL, Pollack GM. Functional evidence for P-glycoprotein at the nose-brain barrier. Pharm Res. 2005;22(1):86–93.
   PubMed Web of Science ®Google Scholar
• Lindemann J, Leiacker R, Rettinger G, et al. Nasal mucosal temperature during respiration. Clin Otolaryngol Allied Sci. 2002;27(3):135–139.
   PubMed Web of Science ®Google Scholar
• Wiesmiller K, Keck T, Leiacker R, et al. Simultaneous in vivo measurements of intranasal air and mucosal temperature. Eur Arch Otorhinolaryngol. 2007;264(6):615–619.
   PubMed Web of Science ®Google Scholar
• Ohwaki T, Ando H, Watanabe S, et al. Effects of dose, pH, and osmolarity on nasal absorption of secretin in rats. J Pharm Sci. 1985;74(5):550–552.
   PubMed Web of Science ®Google Scholar
• Sharpe SA, Sandweiss V, Tuazon J, et al. Comparison of the flow properties of aqueous suspension corticosteroid nasal sprays under differing sampling conditions. Drug Dev Ind Pharm. 2003;29(9):1005–1012.
   PubMed Web of Science ®Google Scholar
• Sosnik A, Das Neves J, Sarmento B. Mucoadhesive polymers in the design of nano-drug delivery systems for administration by non-parenteral routes: a review. Prog Polym Sci. 2014;39(12):2030–2075.
   Web of Science ®Google Scholar
• Ong W-Y, Shalini S-M, Costantino L. Nose-to-brain drug delivery by nanoparticles in the treatment of neurological disorders. Curr Med Chem. 2014;21(37):4247–4256.
   PubMed Web of Science ®Google Scholar
• Boche M, Pokharkar V. Quetiapine nanoemulsion for intranasal drug delivery: evaluation of brain-targeting efficiency. AAPS PharmSciTech. 2017;18(3):686–696.
   PubMed Web of Science ®Google Scholar
• Kim D, Kim YH, Kwon S. Enhanced nasal drug delivery efficiency by increasing mechanical loading using hypergravity. Sci Rep. 2018;8(1):168.
   PubMedGoogle Scholar
• Yuan H, Wang LL, Du YZ, et al. Preparation and characteristics of nanostructured lipid carriers for control-releasing progesterone by melt-emulsification. Colloids Surf B. 2007;60(2):174–179.
   PubMed Web of Science ®Google Scholar
• Vyas TK, Shahiwala A, Marathe S, et al. Intranasal drug delivery for brain targeting. Curr Drug Deliv. 2005;2(2):165–175.
   PubMedGoogle Scholar
• Pardeshi CV, Belgamwar VS. Direct nose to brain drug delivery via integrated nerve pathways bypassing the blood–brain barrier: an excellent platform for brain targeting. Expert Opin Drug Deliv. 2013;10(7):957–972.
   PubMed Web of Science ®Google Scholar
• Warnken ZN, Smyth HD, Watts AB, et al. Formulation and device design to increase nose to brain drug delivery. J Drug Deliv Sci Technol. 2016;35:213–222.
   Web of Science ®Google Scholar
• Mistry A, Stolnik S, Illum L. Nanoparticles for direct nose-to-brain delivery of drugs. Int J Pharm. 2009;379(1):146–157.
   PubMed Web of Science ®Google Scholar
• Prasanthi N, Roy H, Jyothi N, et al. A brief review on chitosan and application in biomedical field. AmJ Pharm Tech Res. 2016;6(4):41–51.
   Google Scholar
• Silki SVR. Enhancement of in vivo efficacy and oral bioavailability of aripiprazole with solid lipid nanoparticles. AAPS PharmSciTech. 2018;19(3):1264–1273.
   PubMed Web of Science ®Google Scholar
• Xu Y, Liu X, Lian R, et al. Enhanced dissolution and oral bioavailability of aripiprazole nanosuspensions prepared by nanoprecipitation/homogenization based on acid-base neutralization. Int J Pharm. 2012;438(1–2):287–295.
   PubMedGoogle Scholar
• Manjunath K, Venkateswarlu V. Pharmacokinetics, tissue distribution and bioavailability of clozapine solid lipid nanoparticles after intravenous and intraduodenal administration. J Control Release. 2005;107(2):215–228.
   PubMed Web of Science ®Google Scholar
• da Costa Güllich AA, Coelho RP, Pilar BC, et al. Clozapine linked to nanocapsules minimizes tissue and oxidative damage to biomolecules lipids, proteins and DNA in brain of rats wistar. Metab Brain Dis. 2015;30(3):695–702.
   PubMed Web of Science ®Google Scholar
• Vieira SM, Michels LR, Roversi K, et al. A surface modification of clozapine-loaded nanocapsules improves their efficacy: A study of formulation development and biological assessment. Colloids Surf B. 2016;145:748–756.
   PubMed Web of Science ®Google Scholar
• Natarajan J, Baskaran M, Humtsoe LC, et al. Enhanced brain targeting efficacy of olanzapine through solid lipid nanoparticles. Artif Cells Nanomed Biotechnol. 2017;45(2):364–371.
   PubMed Web of Science ®Google Scholar
• Babanejad N, Nabid MR, Farhadian A, et al. Sustained delivery of olanzapine from sunflower oil-based polyol-urethane nanoparticles synthesised through a cyclic carbonate ring-opening reaction. IET Nanobiotechnol. 2019;13(7):703–711.
   PubMed Web of Science ®Google Scholar
• Yasir M, Gaur PK, Puri D, et al. Solid lipid nanoparticles approach for lymphatic targeting through intraduodenal delivery of quetiapine fumarate. Curr Drug Deliv. 2018;15(6):818–828.
   PubMed Web of Science ®Google Scholar
• Carreño F, Paese K, Silva CM, et al. Pharmacokinetic investigation of quetiapine transport across blood-brain barrier mediated by lipid core nanocapsules using brain microdialysis in rats. Mol Pharm. 2016;13(4):1289–1297.
   PubMedGoogle Scholar
• Narala A, Veerabrahma K. Preparation, characterization and evaluation of quetiapine fumarate solid lipid nanoparticles to improve the oral bioavailability. J Pharm (Cairo). 2013;2013:265741.
   PubMedGoogle Scholar
• Alzubaidi AFA, El-Helw A-RM, Ahmed TA, et al. The use of experimental design in the optimization of risperidone biodegradable nanoparticles: in vitro and in vivo study. Artif Cells Nanomed Biotechnol. 2017;45(2):313–320.
   PubMed Web of Science ®Google Scholar
• Muthu MS, Rawat MK, Mishra A, et al. PLGA nanoparticle formulations of risperidone: preparation and neuropharmacological evaluation. Nanomedicine. 2009;5(3):323–333.
   PubMed Web of Science ®Google Scholar
• Đorđević SM, Cekić ND, Savić MM, et al. Parenteral nanoemulsions as promising carriers for brain delivery of risperidone: design, characterization and in vivo pharmacokinetic evaluation. Int J Pharm. 2015;493(1–2):40–54.
   PubMedGoogle Scholar
• Agrawal M, Saraf S, Saraf S, et al. Nose-to-brain drug delivery: an update on clinical challenges and progress towards approval of anti-Alzheimer drugs. J Control Release. 2018;281:139–177.
   PubMed Web of Science ®Google Scholar
• Fan Y, Chen M, Zhang J, et al. Updated progress of nanocarrier-based intranasal drug delivery systems for treatment of brain diseases. Crit Rev Ther Drug Carrier Syst. 2018;35:5.
   Web of Science ®Google Scholar
• Thorat SR. Formulation and product development of nasal spray: an overview. Sch J Appl Med Sci. 2016;4:2976–2985.
   Google Scholar
• Erdő F, Bors LA, Farkas D, et al. Evaluation of intranasal delivery route of drug administration for brain targeting. Brain Res Bull. 2018;143:155–170.
   PubMed Web of Science ®Google Scholar
• Costantino HR, Illum L, Brandt G, et al. Intranasal delivery: physicochemical and therapeutic aspects. Int J Pharm. 2007;337(1–2):1–24.
   PubMedGoogle Scholar
• Sawant K, Pandey A, Patel S. Aripiprazole loaded poly(caprolactone) nanoparticles: optimization and in vivo pharmacokinetics. Mater Sci Eng C Mater Biol Appl. 2016;66:230–243.
   PubMed Web of Science ®Google Scholar
• Abdelbary GA, Tadros MI. Brain targeting of olanzapine via intranasal delivery of core-shell difunctional block copolymer mixed nanomicellar carriers: in vitro characterization, ex vivo estimation of nasal toxicity and in vivo biodistribution studies. Int J Pharm. 2013;452(1–2):300–310.
   PubMedGoogle Scholar
• Baltzley S, Mohammad A, Malkawi AH, et al. Intranasal drug delivery of olanzapine-loaded chitosan nanoparticles. AAPS PharmSciTech. 2014;15(6):1598–1602.
   PubMed Web of Science ®Google Scholar
• Gadhave DG, Tagalpallewar AA, Kokare CR. Agranulocytosis-protective olanzapine-loaded nanostructured lipid carriers engineered for cns delivery: optimization and hematological toxicity studies. AAPS PharmSciTech. 2019;20(1):22.
   PubMed Web of Science ®Google Scholar
• Kumar M, Misra A, Babbar AK, et al. Intranasal nanoemulsion based brain targeting drug delivery system of risperidone. Int J Pharm. 2008;358(1–2):285–291.
   PubMed Web of Science ®Google Scholar
• Li J-C, Zhang W-J, Zhu J-X, et al. Preparation and brain delivery of nasal solid lipid nanoparticles of quetiapine fumarate in situ gel in rat model of schizophrenia. Int J Clin Exp Med. 2015;8(10):17590–17600.
   PubMed Web of Science ®Google Scholar
• Patel S, Chavhan S, Soni H, et al. Brain targeting of risperidone-loaded solid lipid nanoparticles by intranasal route. J Drug Target. 2011;19(6):468–474.
   PubMed Web of Science ®Google Scholar
• Rukmangathen R, Yallamalli IM, Yalavarthi PR. Formulation and biopharmaceutical evaluation of risperidone-loaded chitosan nanoparticles for intranasal delivery. Drug Dev Ind Pharm. 2019;45(8):1342–1350.
   PubMed Web of Science ®Google Scholar
• Seju U, Kumar A, Sawant KK. Development and evaluation of olanzapine-loaded PLGA nanoparticles for nose-to-brain delivery: in vitro and in vivo studies. Acta Biomater. 2011;7(12):4169–4176.
   PubMed Web of Science ®Google Scholar
• Shah B, Khunt D, Misra M, et al. Application of box-behnken design for optimization and development of quetiapine fumarate loaded chitosan nanoparticles for brain delivery via intranasal route. Int J Biol Macromol. 2016;89:206–218.
   PubMed Web of Science ®Google Scholar
• Salvador-Morales C, Zhang L, Langer R, et al. Immunocompatibility properties of lipid–polymer hybrid nanoparticles with heterogeneous surface functional groups. Biomaterials. 2009;30(12):2231–2240.
   PubMed Web of Science ®Google Scholar
• Fröhlich E. The role of surface charge in cellular uptake and cytotoxicity of medical nanoparticles. Int J Nanomedicine. 2012;7:5577.
   PubMed Web of Science ®Google Scholar
• Li H, Chen Y, Deng Y, et al. Effects of surface charge of low molecular weight heparin-modified cationic liposomes on drug efficacy and toxicity. Drug Dev Ind Pharm. 2017;43(7):1163–1172.
   PubMed Web of Science ®Google Scholar
• Clogston JD, Patri AK. Zeta potential measurement. Characterization of nanoparticles intended for drug delivery. New York(NY): Springer; 2011. p. 63–70.
   Google Scholar
• Banik BL, Fattahi P, Brown JL. Polymeric nanoparticles: the future of nanomedicine. Wiley Interdiscip Rev Nanomed Nanobiotechnol. 2016;8(2):271–299.
   PubMed Web of Science ®Google Scholar
• Kamaly N, Yameen B, Wu J, et al. Degradable controlled-release polymers and polymeric nanoparticles: mechanisms of controlling drug release. Chem Rev. 2016;116(4):2602–2663.
   PubMed Web of Science ®Google Scholar
• Masserini M. Nanoparticles for brain drug delivery. ISRN Biochemistry. 2013;2013:238428.
   Google Scholar
• Muthu MS, Sahu AK, Sonali AA, et al. Solubilized delivery of paliperidone palmitate by D-alpha-tocopheryl polyethylene glycol 1000 succinate micelles for improved short-term psychotic management. Drug Deliv. 2016;23(1):230–237.
   PubMed Web of Science ®Google Scholar
• Singh R, Lillard JW Jr. Nanoparticle-based targeted drug delivery. Exp Mol Pathol. 2009;86(3):215–223.
   PubMed Web of Science ®Google Scholar
• Patra JK, Das G, Fraceto LF, et al. Nano based drug delivery systems: recent developments and future prospects. J Nanobiotechnology. 2018;16(1):71.
   PubMed Web of Science ®Google Scholar
• El-Say KM, El-Sawy HS. Polymeric nanoparticles: promising platform for drug delivery. Int J Pharm. 2017;528(1):675–691.
   PubMedGoogle Scholar
• Danhier F, Ansorena E, Silva JM, et al. PLGA-based nanoparticles: an overview of biomedical applications. J Control Release. 2012;161(2):505–522.
   PubMed Web of Science ®Google Scholar
• Sherje AP, Londhe V. Development and evaluation of pH-responsive cyclodextrin-based in situ gel of paliperidone for intranasal delivery. AAPS PharmSciTech. 2018;19(1):384–394.
   PubMed Web of Science ®Google Scholar
• Makhlouf A, Abu-Thabit N. Stimuli responsive polymeric nanocarriers for drug delivery applications. San Diego: Elsevier Science & Technology; 2018.
   Google Scholar
• Mohapatra S, Ranjan S, Dasgupta N, et al. Characterization and biology of nanomaterials for drug delivery: nanoscience and nanotechnology in drug delivery. Amsterdam, Netherlands: Elsevier; 2019.
   Google Scholar
• Akbarzadeh A, Rezaei-Sadabady R, Davaran S, et al. Liposome: classification, preparation, and applications. Nanoscale Res Lett. 2013;8(1):102.
   PubMed Web of Science ®Google Scholar
• Upadhyay P, Trivedi J, Pundarikakshudu K, et al. Direct and enhanced delivery of nanoliposomes of anti schizophrenic agent to the brain through nasal route. Saudi Pharm J. 2017;25(3):346–358.
   PubMed Web of Science ®Google Scholar
• Pantze SF, Parmentier J, Hofhaus G, et al. Matrix liposomes: a solid liposomal formulation for oral administration. Eur J Lipid Sci Tech. 2014;116(9):1145–1154.
   Web of Science ®Google Scholar
• Chu C, Tong SS, Xu Y, et al. Proliposomes for oral delivery of dehydrosilymarin: preparation and evaluation in vitro and in vivo. Acta Pharmacol Sin. 2011;32(7):973.
   PubMed Web of Science ®Google Scholar
• Payne NI, Ambrose CV, Timmins P, et al. Proliposomes: a novel solution to an old problem. J Pharm Sci. 1986;75(4):325–329.
   PubMed Web of Science ®Google Scholar
• Müller RH, Mäder K, Gohla S. Solid lipid nanoparticles (SLN) for controlled drug delivery - a review of the state of the art. Eur J Pharm Biopharm. 2000;50(1):161–177.
   PubMed Web of Science ®Google Scholar
• Zara GP, Cavalli R, Bargoni A, et al. Intravenous administration to rabbits of non-stealth and stealth doxorubicin-loaded solid lipid nanoparticles at increasing concentrations of stealth agent: pharmacokinetics and distribution of doxorubicin in brain and other tissues. J Drug Target. 2002;10(4):327–335.
   PubMed Web of Science ®Google Scholar
• Singh SK, Dadhania P, Vuddanda PR, et al. Intranasal delivery of asenapine loaded nanostructured lipid carriers: formulation, characterization, pharmacokinetic and behavioural assessment. RSC Adv. 2016;6(3):2032–2045.
   Web of Science ®Google Scholar
• Ranpise NS, Korabu SS, Ghodake VN. Second generation lipid nanoparticles (NLC) as an oral drug carrier for delivery of lercanidipine hydrochloride. Colloids Surf B. 2014;116:81–87.
   PubMed Web of Science ®Google Scholar
• Shao Z, Shao J, Tan B, et al. Targeted lung cancer therapy: preparation and optimization of transferrin-decorated nanostructured lipid carriers as novel nanomedicine for co-delivery of anticancer drugs and DNA. Int J Nanomedicine. 2015;10:1223–1233.
   PubMed Web of Science ®Google Scholar
• Li Q, Cai T, Huang Y, et al. A review of the structure, preparation, and application of NLCs, PNPs, and PLNs. Nanomaterials (Basel). 2017;7(6):122.
   PubMedGoogle Scholar
• Borst P, Zelcer N, van Helvoort A. ABC transporters in lipid transport. Biochim Biophys Acta. 2000;1486(1):128–144.
   PubMed Web of Science ®Google Scholar
• Basel MT, Shrestha TB, Troyer DL, et al. Protease-sensitive, polymer-caged liposomes: a method for making highly targeted liposomes using triggered release. ACS Nano. 2011;5(3):2162–2175.
   PubMed Web of Science ®Google Scholar
• Mandal B, Bhattacharjee H, Mittal N, et al. Core-shell-type lipid-polymer hybrid nanoparticles as a drug delivery platform. Nanomedicine. 2013;9(4):474–491.
   PubMed Web of Science ®Google Scholar
• Schillemans JP, Flesch FM, Hennink WE, et al. Synthesis of bilayer-coated nanogels by selective cross-linking of monomers inside liposomes. Macromolecules. 2006;39(17):5885–5890.
   Web of Science ®Google Scholar
• Dave V, Tak K, Sohgaura A, et al. Lipid-polymer hybrid nanoparticles: synthesis strategies and biomedical applications. J Microbiol. 2019;160:130–142.
   Google Scholar
• Mukherjee A, Waters AK, Kalyan P, et al. Lipid-polymer hybrid nanoparticles as a next-generation drug delivery platform: state of the art, emerging technologies, and perspectives. Int J Nanomedicine. 2019;14:1937–1952.
   PubMed Web of Science ®Google Scholar
• Helal HM, Mortada SM, Sallam MA. Paliperidone-loaded nanolipomer system for sustained delivery and enhanced intestinal permeation: superiority to polymeric and solid lipid nanoparticles. AAPS PharmSciTech. 2017;18(6):1946–1959.
   PubMed Web of Science ®Google Scholar
• Bantz C, Koshkina O, Lang T, et al. The surface properties of nanoparticles determine the agglomeration state and the size of the particles under physiological conditions. Beilstein J Nanotechnol. 2014;5(1):1774–1786.
   PubMedGoogle Scholar